Nancy Bartlett, MD

Medical Oncologist

Nancy Bartlett

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108
Siteman Cancer Center at Barnes-Jewish West County Hospital

Siteman Cancer Center at Barnes-Jewish West County Hospital

Medical Office Building 2, 10 Barnes West Drive, Creve Coeur, MO 63141

Expertise & Training

Clinical Expertise

  • Hematologic Malignancies

  • Lymphoma

Primary Academic Title

Professor of Medicine, Division of Oncology, Koman Chair in Medical Oncology, WashU Medicine

Board Certification

  • 1989: American Board of Internal Medicine, Internal Medicine
  • 1993: American Board of Internal Medicine, Medical Oncology
  • 2003: American Board of Internal Medicine, Medical Oncology

Training

  • 1986 - 1990: Intern and Resident, Internal Medicine, University of California, San Francisco, CA
  • 1990 - 1994: Postdoctoral Fellow, Medical Oncology, Stanford University, Stanford, CA

Education

  • 1986: MD, WashU Medicine, St. Louis, MO

Research & Selected Publications

Research Interest

Clinical trials for patients with high risk or recurrent non-Hodgkin’s lymphoma and Hodgkin’s disease

Research Publications

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis
Authors:

Bartlett NL, Sehn LH, Assouline S, one or more additional authors omitted Budde LE

Journal & Year:

Am J Hematol | 2026

A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma
Authors:

Diefenbach CS, Jegede O, Wang V, one or more additional authors omitted Bartlett NL, one or more additional authors omitted Kahl BS

Journal & Year:

Blood | 2026

Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma
Authors:

Abramson JS, Straus DJ, Bartlett NL, one or more additional authors omitted Lee HJ

Journal & Year:

Blood | 2026

New Standards in Advanced-stage Hodgkin Lymphoma: Selecting a Novel Regimen
Authors:

Cochran HC, Bartlett NL

Journal & Year:

Hematol Oncol Clin North Am | 2026

To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphoma
Authors:

Russler-Germain DA, Bartlett NL

Journal & Year:

Haematologica | 2026

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
Authors:

Zelenetz AD, Gordon LI, Abramson JS, one or more additional authors omitted Bartlett NL, one or more additional authors omitted Sundar H

Journal & Year:

J Natl Compr Canc Netw | 2025

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Di…
Authors:

Andreadis C, Bobek O, Hsi ED, one or more additional authors omitted Bartlett NL

Journal & Year:

Leuk Lymphoma | 2025

Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
Authors:

Rutherford SC, Li H, Herrera AF, one or more additional authors omitted Bartlett NL, one or more additional authors omitted Evens AM

Journal & Year:

J Clin Oncol | 2025